Zurek AM, Yendapally R, Urteaga EM A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Kosiborod M, Cavender MA, Fu AZ, et al.Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2
Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor,
Inzucchi SE, Zinman B, Fitchett D, et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights from a Mediation Analysis of the EMPA-REG OUTCOME Trial
Scheen AJ Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization?
Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness
Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction
Luconi M, Raimondi L, Di Franco A, et al. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places
Ferrannini E, Baldi S, Frascerra S, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects without Diabetes and Patients with Type 2 Diabetes
Verma S, McMurray JJV SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Ferrannini E, Mark M, Mayoux E CV Protection in the EMPA-REG OUTCOME Trial: A « Thrifty Substrate »
Gormsen LC, Svart M, Thomsen HH, et al. Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
Baartscheer A, Schumacher CA, Wüst RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+
Regan TJ, Lehan PH, Henneman DH, et al. Myocardial metabolic and contractile response to glucagon
Méry PF, Brechler V, Pavoine C, et al. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase
Jones BJ, Tan T, Bloom SR Minireview: Glucagon in stress and energy homeostasis
Lee TM, Chang NC, Lin SZ Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis
Patel VB, Shah S, Verma S, et al. Epicardial adipose tissue as a metabolic transducer: role in heart failure
Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume
Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines.
